Editor’s highlights from the Journal of Comparative Effectiveness Research – November 2022
In this monthly column, I share some of my highlights from the latest issues of the Journal of Comparative Effectiveness Research, partner journal of The Evidence Base.
November is a busy month for the HEOR community, with the annual ISPOR Europe event (this year in Vienna, Austria) giving many of us a chance to meet in-person and learn about the most recent research and hot topics in the field. The November issue of the Journal of Comparative Effectiveness Research also includes a wide array of content, and below I share some of my picks from the issue. You can view issue 16 in full here.
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 9
In their regular Industry Update article, Simpson and Ramagopalan (F Hoffmann-La Roche, Switzerland) share their round-up of developments in RWE relating to HTA. In this instalment, they highlight a recent ISPOR Good Practice Report on machine learning for health economics and outcomes research and discuss use cases for RWE generation.
Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case–control design
In their Research Article, Reynolds et al. (IQVIA, MA, USA) investigated the real-world effectiveness of three COVID-19 vaccines using a modified test-negative design. Included in the study were vaccines from Janssen, Moderna and Pfizer, and the investigators used self-reported data from the COVID-19 Active Research Experience (CARE) registry’s US community-based on-line registry, first launched in March 2020. The study found high effectiveness across all three marketed vaccines, and the authors highlighted the importance of studying the extent to which the real-world effectiveness of marketed vaccines is consistent with that observed in the clinical trials.
The societal impact of early intensified treatment in patients with type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) is a serious health condition, and is associated with a high risk for multi-system complications, including cardiovascular diseases. In a new study from Tsotra (WifOR Institute, Greece), researchers assessed the health and socio-economic implications associated with early intensified T2DM treatment in Mexico (as an exemplar LMIC), using an individual patient-level simulation, a population model and a socio-economic evaluation, over a period of 10 years.
I hope you enjoy these articles, along with the rest of the content of the November issue. The journal welcomes presubmission enquiries, so should you be interested in submitting your work, please do get in touch.